A Novel Fusion Protein for Inhibiting HIV Budding


Ubiquitin plays a critical role in HIV-1 budding. Vectors containing deubiquitin enzymes (DUbs) were constructed to deliver DUbs to HIV-1 production sites in living cells. The DUbs vectors comprise DUb cDNAs and cDNA expressing either HIV-1 gag, or the ESCRT protein TSG101.

Experimental data show that the fusion proteins expressed by the DUbs vectors retained their known protein-protein interactions and caused a significant and specific interruption of HIV-1 budding. The data suggest that the DUbs vectors could be used to inhibit HIV-1 infection or propagation in an individual. Thus, the DUbs vectors could potentially be used in high-risk individuals to prevent HIV-1 infection or as an adjunct therapy with known Anti-Retroviral Therapy (ART/HAART) in infected individuals.

Potential Commercial Applications: Competitive Advantages:
  • Prevention for HIV
  • Treatment for patients infected with HIV
  • Clinical research
 
  • Use for both treatment and prevention
  • No development of resistance to HIV


Development Stage:
In vitro data available

Inventors:

Fadila Bouamr (NIAID)  ➽ more inventions...

Paola Sette (NIAID)  ➽ more inventions...


Intellectual Property:
PCT Application No. PCT/US2015/042492
US Application No. 62/030,193

Publications:
Sette P, et al. PMID 23895345

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the DUbs vectors and/or the fusion proteins expressed by the vectors. For collaboration opportunities, please contact Fadilla Bouamr, Ph.D. at bouamrf@niaid.nih.gov.


Licensing Contact:
Peter Tung, Ph.D., M.B.A.
Email: peter.tung@nih.gov
Phone: 240-669-5483

OTT Reference No: E-223-2014-0
Updated: May 10, 2018